Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation

Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy

Potential effects of anti‐CTLA‐4 and anti‐PD‐1 combination therapy on T

Cancers, Free Full-Text

The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Cytotoxic T lymphocyte-associated antigen-4 blockade restores T cell

Smart drug delivery systems to overcome drug resistance in cancer immunotherapy

Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy

Full article: Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma